- Home
- ICCM vs ALGS Comparison
ICCM vs ALGS Comparison
Compare ICCM & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | ALGS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 43.0M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ICCM | ALGS |
|---|---|---|
| Price | $0.61 | $6.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $46.67 |
| AVG Volume (30 Days) | ★ 150.4K | 33.8K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $31.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $3.76 |
| 52 Week High | $1.53 | $13.69 |
Technical Indicators
Market Signals| Indicator | ICCM | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 47.30 |
| Support Level | $0.59 | $6.92 |
| Resistance Level | $0.62 | $7.50 |
| Average True Range (ATR) | 0.04 | 0.55 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 45.76 | 65.13 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.